Biosimilars Striving for US Uptake

DOI:

https://doi.org/10.37285/ijpsn.2018.11.6.1

Authors

  • Bobby George

Abstract

Though biosimilars have to go through an abbreviated regulatory pathway for approval, it is quite challenging given the scientific and technical complexities associated with these products. As an increasing number of biologics face patent expiration, biosimilars offer an attractive opportunity. While companies would be desiring to have a footing in the developed markets like US and EU, considerable opportunities exist in developing/emerging markets. With more number of biosimilars making their commercial foray, starting to gain acceptance across formularies, the leading biologic players have started taking a hit on price, volume and market share of their blockbuster drugs. The pace of sales erosion due to biosimilars is expected to be gradual yet relentless. Since the enactment of Biologics Price Competition and Innovation (BPCI) Act, 12 biosimilars have been approved by the US Food and Drug Administration (FDA) till September 2018. However, only a small percentage have seen the light of the day in terms of commercial launches. These are primarily driven by legal challenges and hesitancy from insurers and healthcare providers. While originators have been trying all the means at their disposal to thwart competition by posing challenges, the biosimilar players are striving to take them head on with the anticipated revenues in mind. Stakeholders have made key recommendations to increase the uptake of biosimilars in US market. Regulatory agencies have to play a key role in promoting confidence in biosimilars among healthcare practitioners and patients. The FDAs much awaited Biosimilars Action Plan (BAP) is expected to revive the sedentary biosimilar market in the US. The medical community, payers, and the FDA should work together for ensuring the approved biosimilars are adopted and prescribed in a manner to bring down overall healthcare costs.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Keywords:

Biosimilars, FDA, Reference biologic, Biosimilars Action Plan

Downloads

Published

2018-11-30

How to Cite

1.
George B. Biosimilars Striving for US Uptake . Scopus Indexed [Internet]. 2018 Nov. 30 [cited 2024 Dec. 11];11(6):4281-6. Available from: https://www.ijpsnonline.com/index.php/ijpsn/article/view/396

References

Angus L (2018). FDA chief Gottlieb blames drug makers for ‘anemic’ biosimilar market. Fierce Pharma. 19 July.
Anna RW (2018). How the regulatory pathway shapes biosimilar business decisions. Biosimilar Development, 29 August.
Biosimilars review and report (2018). Available from: https:// biosimilarsrr.com/us-biosimilar-filings/ Last accessed on 12 September 2018.
Bobby G (2016). Changes in regulatory requirements for biosimilar development in India. Biosimilar Development, 22 November.
Bobby G (2018). Chapter 9: ‘Biosimilar Acts’. In: The Act that Wasn’t® (Ed 2). ISBN 978-93-84334-77-2. Self-published, India.
Callaghan JO, Barry SP, Bermingham M, Morris JM and Griffin BT (2018). Regulation of biosimilar medicines and current perspectives on interchangeability and policy. European J. of Clin. Pharmacol. 05 September.
EMA:https://www.ema.europa.eu/en/medicines/field_ema_web_categories%253Aname_field/Human/field_ema_web_categories%253Aname_field/Medicines/ema_medicine_types/field_ema_med_biosimilar/ema_group_types/ema_medicine/field_ema_med_status/authorised-36. Last accessed on 12 September 2018
Food and Drug Administration (2018). Biosimilars Action Plan: Balancing innovation and competition. Available from: http://www.fda.gov. July.
Gary HL, Robin Z, Donald H and Richard LS (2018). Rationale, opportunities, and reality of biosimilar medications. N Engl J Med 378: 2036-44.
IMS Health (2016). The impact of biosimilar competition. London: QuintilesIMS, June.
Jacoby R, Erik S, Drew W, Divya I and Sophie P (2015). Winning with biosimilars. Opportunities in global markets. Delloite. Last accessed on 28 September 2018.
Jennifer F (2018). Biosimilars: Challenges and barriers to entering the U.S market. Biopharm. Processing. 56-59.
Joe M (2018). Doubling up for speed: Using parallel operations in biopharma manufacturing. BioProcess Online.
Kay J, Schoels MM, Dörner T, et al., (2018). Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis. 77: 165-174.
Leela T (2018). What’s new in US Biosimilar-Land? Bioradiations.
Mark T (2018) Trump Signs FTC Law That Allows for Biosimilar Scrutiny. BioSpace.
Mulcahy AW, Hlavka JP and Case SR (2017). Biosimilar cost savings in the United States: Initial experience and future potential. Santa Monica, CA: RAND Corporation.
Ned P (2018a). FDA confronts its limits in push on drug pricing. Biosimilar Development.
Ned P (2018b). Biosimilars bite into Herceptin in Europe. Biopharma Dive.
Samantha D (2018). IGBA asks FDA to waive bridging study requirements for biosimilars. Centerforbiosimilars.com.
Saranraj S (2017). Emerging markets hold the potential for makers of biosimilars. Whitepapers - beroeinc.com.
Sarfaraz KN (2018a). Rationalizing FDA guidance on biosimilars - expediting approvals and acceptance. Generics & Biosimilar initiative J. 7(2): 23.
Sarfaraz KN (2018b). Obstacles to success for biosimilars in the US market. European Pharmaceutical Review.
World Health Organization (2018). WHO Questions and Answers: Similar biotherapeutic products. WHO/BS/2018.2352.
Ylenia I, Paola MC, Ilaria M, Thijis G, Fabiola A and Gianluca T (2018). Safety of biologics including biosimilars: Perspectives on current status and future direction. Drug Safety.